Runner dies during the Brooklyn Half Marathon: Officials
It was the runner's first time participating in the race, according to officials.
More Local News
Officials say the runner experienced a medical episode around mile eight of the 13-mile course.
CPR was administered onsite to the runner.
He was taken to a local hospital to be treated for his medical episode. He was later pronounced dead, officials said.
It is with sadness and heavy hearts that we confirm the passing of one of today's race participants. On behalf of the whole running community, we extend our deepest condolences to his family, friends and loved ones.
Rob Simmelkjaer, CEO, New York Road Runners
NYRR noted that each race has medical staff on-site, including doctors, nurses, physician assistants, EMTs, paramedics, and other trained personnel. Officials note runner safety is a major priority.
The identity of the runner has not been released.
Matthew Euzarraga is a multimedia journalist from El Paso, Texas. He has covered local news and LGBTQIA topics in the New York City Metro area since 2021. He joined the PIX11 Digital team in 2023. You can see more of his work here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy. Unsold completed new-build inventory is so high this $34B homebuilder is turning to investors 'Job hugging' is the newest career trend: Here's what it means—and why Gen Z is into it Spotify just redesigned the way you'll 'listen' to audiobooks According to a press release posted early on August 18, GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to 'eligible self-paying customers.' GoodRx doesn't sell or dispense any drugs itself, but rather provides savings and coupons that can be applied in pharmacies. Its exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market. The news comes just weeks after Novo Nordisk cut ties with the telehealth company Hims & Hers Health (NYSE: HIMS) over claims that Hims & Hers was selling 'knockoff' versions of Wegovy. It's a dispute that reflects a broader discussion around whether compounded semaglutide drugs—or non-FDA approved versions of brand-name medicines—are a violation of intellectual property laws. As of this writing, GoodRx's stock is up by more than 30% since market close. Here's what to know about Novo Nordisk's latest partnership and its ongoing legal battles against compounded GLP-1s. GoodRx's collaboration with Novo Nordisk In the last year alone, GoodRx reports that nearly 17 million people visited the site searching for information and savings on GLP-1 medications—a 22% increase from the previous year. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' Wendy Barnes, GoodRX president and CEO, said in the press release. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them.' In the past, a spokesperson told Fast Company, GoodRx has worked with both Novo Nordisk and its competitor Eli Lilly to offer commercially insured patients manufacturer savings cards on GLP-1s. The company has also offered savings on other types of weight loss/diabetes treatments, including Contrave, Dexcom G7, Lantus, and Qsymia. However, this is the first time that GoodRx has offered a cash price for a GLP-1. The $499 monthly self-pay cost will be available at more than 70,000 retail locations nationwide. Novo Nordisk's current legal battles over compounded GLP-1s So far, investors' response to GoodRx's new collaboration has been overwhelmingly positive. It stands in sharp contrast to Hims & Hers' recent breakup with Novo Nordisk, which caused the telehealth company's share prices to plummet in late June. Hims & Hers and Novo Nordisk parted ways over Hims & Hers' offering of compounded versions of Wegovy. Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand-name drugs using their active ingredient, semaglutide, and sell them at a lower cost. However, Hims & Hers has continued to sell its compounded version of Wegovy long after the FDA lifted the shortage back in February. Now, Novo Nordisk is arguing that these compounded drugs are both a violation of its intellectual property and potentially dangerous to patients, due to their lack of FDA approval. Early this month, Novo Nordisk announced 14 new lawsuits against small pharmacies, telehealth providers, and weight-loss clinics over compounded versions of Ozempic and Wegovy—bringing its total cases filed on the matter up to more than 130 in 40 states. Experts say that federal compounding laws are just vague enough to allow for various interpretations, meaning that Novo Nordisk's current legal challenges could shape the way courts interpret those boundaries in the future. In a statement to Yahoo Finance, Barnes offered a clear look into GoodRx's stance on compounded drugs: 'There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support,' she said. This post originally appeared at to get the Fast Company newsletter:
Yahoo
31 minutes ago
- Yahoo
RFK Jr. attacks pediatricians' group over vaccine recommendations
The gloves are off in Robert F. Kennedy Jr.'s feud with American doctors. Hours after the American Academy of Pediatrics, the professional society for doctors who care for children, issued Covid-19 vaccine guidance contradicting that of the health secretary, Kennedy accused the group of engaging in a 'pay-to-play scheme to promote commercial ambitions of AAP's Big Pharma benefactors' in a post on social media platform X. Kennedy cited donations from Covid mRNA vaccine drugmakers Pfizer and Moderna, among other pharmaceutical companies, to the pediatricians' Friends of Children Fund, which backs projects promoting children's health and health equity. Kennedy said the contributions constituted a conflict of interest and suggested they led to the group's decision to recommend that young children, between 6 and 23 months old, receive Covid vaccines. In May, the Centers for Disease Control and Prevention dropped its recommendation that all children 6 months and older get Covid shots. Kennedy at the time said the move was based on 'common sense' and 'good science.' The AAP, however, said it had retained its guidance for young children to get the shots because they are still at risk of severe cases of the disease. 'COVID-19 continues to result in hospitalization and death in the pediatric population,' the group said in a release explaining its recommendations, adding that 'children younger than 2 years old are especially vulnerable to severe COVID-19 and should be prioritized for vaccination.' The pediatric group did not immediately respond to POLITICO's request for comment regarding Kennedy's remarks. Earlier Tuesday, HHS spokesperson Andrew Nixon accused the pediatricians of 'freelancing its own recommendations, while smearing those who demand accountability' in a statement to POLITICO. AAP President Susan J. Kressly defended her group's guidance in response, saying they were 'based only in the science, the needs of children, and the care that pediatricians have for the children in every community.' Despite the disagreement over vaccination of young children, both the new CDC guidance and the pediatricians continue to recommend shots for children with underlying conditions that could put them at risk for severe disease. Both have also scaled back recommendations for healthy children older than 6 months, saying that parents of children without underlying conditions should decide on vaccination in consultation with their pediatrician. Why it matters: The pediatricians' split with the CDC underscores the depth of the distrust between the medical establishment and Kennedy — a longtime vaccine skeptic who once said the Covid vaccine was 'the deadliest vaccine ever made' in defiance of scientific consensus. Before Kennedy's arrival, the agency and the pediatricians agreed on vaccine recommendations, but Kennedy's efforts to overhaul federal vaccine policy have upset the relationship. Earlier this summer, he ousted all the members of the expert panel that advises the CDC on vaccines, the Advisory Committee on Immunization Practices, tapping new members with a history of vaccine skepticism. Most recently, Kennedy rescinded $500 million earmarked for research into mRNA technology, which was used to develop the Moderna and Pfizer Covid vaccines. And his latest post isn't the first time he's criticized doctors. The May report from his Make America Health Again Commission assessing the causes of chronic disease in children was laced with accusations that doctors are influenced by the pharmaceutical industry to overprescribe certain medications and fail to treat the root causes of disease. The split also comes as children return to school and the annual fall vaccination campaign for Covid and the flu is beginning. Kennedy suggested that the pediatric group could be exposing its member doctors to liability in his X post, stating that 'AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act.' The National Vaccine Injury Compensation Program, which that law created, doesn't cover Covid vaccines, but Kennedy has said he wants to overhaul the system for compensating people who experience serious side effects from vaccines. He would likely need Congress' assent to change it.
Digital Trends
33 minutes ago
- Digital Trends
NASA and Google are testing an AI space doctor
With NASA eyeing long-duration crewed missions to the moon and beyond in the coming years, it has to be sure that if a medical situation arises, the astronauts are well equipped to deal with it. Currently, crews heading to the International Space Station (ISS) receive training for basic medical procedures and medicines, as well as for things like intravenous fluid administration, intubation, wound care, and basic emergency response. Recommended Videos But future missions that take humans hundreds of thousands — or even millions — of miles from Earth, potentially for years at a time, will add a new layer of complexity to health management. With that in mind, the U.S. space agency has partnered with Google on a project aimed at ensuring crew health and wellness on long-duration missions. The initiative includes an investigation into whether remote care capabilities can offer detailed diagnoses and treatment options when a health issue falls outside of the astronauts' knowledge base, and when real-time communication with Earth is limited. NASA and Google's work involves a proof-of-concept for an automated Clinical Decision Support System (CDSS) known as the 'Crew Medical Officer Digital Assistant' (CMO-DA). 'Designed to assist astronauts with medical help during extended space missions, this multi-modal interface leverages AI,' Google said in an online post. It said the CMO-DA tool could help astronauts 'autonomously diagnose and treat symptoms when crews are not in direct contact with Earth-based medical experts.' It added: 'Trained on spaceflight literature, the AI system uses cutting-edge natural language processing and machine learning techniques to safely provide real-time analyses of crew health and performance. The tool is designed to support a designated crew medical officer or flight surgeon in maintaining crew health and making medical decisions driven by data and predictive analytics.' Early results from initial trials have 'showed promise' for obtaining reliable diagnoses based on reported symptoms. Moving forward, NASA and Google are now working with medical doctors to improve the technology with a view to using it on future space missions. As part of NASA's Artemis program, astronauts could one stay for extended periods aboard a lunar satellite — similar to how they live and work aboard the ISS today — or even on the moon itself. More ambitious endeavors, such as to Mars, are also on the cards, but aren't expected to take place until the 2030s at the earliest.
